Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
August 8, 2021
Chronic migraine in the first COVID-19 lockdown: the impact of sleep, remote working, and other life/psychological changes
Carmelo Tiberio Currò, Antonio Ciacciarelli, Chiara Vitale, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
September 22, 2022
Sleep and sleep-modifying factors in chronic migraine patients during the COVID-19 lockdown
Carmelo Tiberio Currò, Antonio Ciacciarelli, Chiara Vitale, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
August 29, 2020
Drug withdrawal along with bridge therapy with methylprednisolone and/or diazepam for treatment of medication overuse headache: a preliminary report from the WASH-OUT study
Fabrizio Vernieri, Patrizio Pasqualetti, Matteo Paolucci, et al.
Brain Sciences
|
July 27, 2024
Evaluating the Effectiveness, Tolerability, and Safety of Eptinezumab in High-Frequency and Chronic Migraine in Real World: EMBRACE-The First Italian Multicenter, Prospective, Real-Life Study
Piero Barbanti, Bianca Orlando, Gabriella Egeo, et al.
Journal of Clinical Medicine
|
May 27, 2023
Erenumab and Possible CGRP Effect on Chronotype in Chronic Migraine: A Real-Life Study of 12 Months Treatment
Laura Pilati, Angelo Torrente, Salvatore Di Marco, et al.
The Journal of Headache and Pain
|
March 23, 2023
Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study
Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.
Neurology and Therapy
|
March 7, 2024
Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
Piero Barbanti, Gabriella Egeo, Stefania Proietti, et al.
Neurology and Therapy
|
August 6, 2024
Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
Piero Barbanti, Gabriella Egeo, Stefania Proietti, et al.
Neurology and Therapy
|
June 9, 2026
Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study
Piero Barbanti, Cinzia Aurilia, Massimo Filippi, et al.
The Journal of Headache and Pain
|
January 31, 2026
Responders and super-responders to atogepant after 24 weeks of treatment in migraine: real-world evidence from the GIANT-2 study
Piero Barbanti, Gabriella Egeo, Alberto Doretti, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
August 8, 2021
Chronic migraine in the first COVID-19 lockdown: the impact of sleep, remote working, and other life/psychological changes
Carmelo Tiberio Currò, Antonio Ciacciarelli, Chiara Vitale, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
September 22, 2022
Sleep and sleep-modifying factors in chronic migraine patients during the COVID-19 lockdown
Carmelo Tiberio Currò, Antonio Ciacciarelli, Chiara Vitale, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
August 29, 2020
Drug withdrawal along with bridge therapy with methylprednisolone and/or diazepam for treatment of medication overuse headache: a preliminary report from the WASH-OUT study
Fabrizio Vernieri, Patrizio Pasqualetti, Matteo Paolucci, et al.
Brain Sciences
|
July 27, 2024
Evaluating the Effectiveness, Tolerability, and Safety of Eptinezumab in High-Frequency and Chronic Migraine in Real World: EMBRACE-The First Italian Multicenter, Prospective, Real-Life Study
Piero Barbanti, Bianca Orlando, Gabriella Egeo, et al.
Journal of Clinical Medicine
|
May 27, 2023
Erenumab and Possible CGRP Effect on Chronotype in Chronic Migraine: A Real-Life Study of 12 Months Treatment
Laura Pilati, Angelo Torrente, Salvatore Di Marco, et al.
The Journal of Headache and Pain
|
March 23, 2023
Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study
Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.
Neurology and Therapy
|
March 7, 2024
Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
Piero Barbanti, Gabriella Egeo, Stefania Proietti, et al.
Neurology and Therapy
|
August 6, 2024
Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
Piero Barbanti, Gabriella Egeo, Stefania Proietti, et al.
Neurology and Therapy
|
June 9, 2026
Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study
Piero Barbanti, Cinzia Aurilia, Massimo Filippi, et al.
The Journal of Headache and Pain
|
January 31, 2026
Responders and super-responders to atogepant after 24 weeks of treatment in migraine: real-world evidence from the GIANT-2 study
Piero Barbanti, Gabriella Egeo, Alberto Doretti, et al.
Page
of 3